Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Niagen Bioscience (NAGE) over the last 10 years, with Sep 2025 value amounting to -$15,000.

  • Niagen Bioscience's Gains from Investment Securities rose 28.57% to -$15,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$59,000, marking a year-over-year increase of 23.38%. This contributed to the annual value of -$80,000 for FY2024, which is 6.67% down from last year.
  • Per Niagen Bioscience's latest filing, its Gains from Investment Securities stood at -$15,000 for Q3 2025, which was down 15.38% from -$13,000 recorded in Q2 2025.
  • Niagen Bioscience's 5-year Gains from Investment Securities high stood at -$13,000 for Q4 2022, and its period low was -$30,000 during Q3 2021.
  • Over the past 3 years, Niagen Bioscience's median Gains from Investment Securities value was -$18,000 (recorded in 2024), while the average stood at -$17,818.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 154.55% in 2021, then soared by 44.83% in 2022.
  • Over the past 5 years, Niagen Bioscience's Gains from Investment Securities (Quarterly) stood at -$21,000 in 2021, then soared by 38.10% to -$13,000 in 2022, then dropped by 15.38% to -$15,000 in 2023, then declined by 20.00% to -$18,000 in 2024, then grew by 28.57% to -$15,000 in 2025.
  • Its Gains from Investment Securities stands at -$15,000 for Q3 2025, versus -$13,000 for Q2 2025 and -$13,000 for Q1 2025.